Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects

Stephen Patterson; Susan Wyllie

doi:10.1016/j.pt.2014.04.003

Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects

Stephen Patterson (Lead / Corresponding author), Susan Wyllie (Lead / Corresponding author)

Biological Chemistry and Drug Discovery

Research output: Contribution to journal › Article › peer-review

260 Citations (Scopus)

236 Downloads (Pure)

Abstract

There is an urgent need for new, safer, and effective treatments for the diseases caused by the protozoan parasites Trypanosoma brucei, Trypanosoma cruzi, and Leishmania spp. In the search for more effective drugs to treat these 'neglected diseases' researchers have chosen to reassess the therapeutic value of nitroaromatic compounds. Previously avoided in drug discovery programs owing to potential toxicity issues, a nitro drug is now being used successfully as part of a combination therapy for human African trypanosomiasis. We describe here the rehabilitation of nitro drugs for the treatment of trypanosomatid diseases and discuss the future prospects for this compound class.

Original language	English
Pages (from-to)	289-298
Number of pages	10
Journal	Trends in Parasitology
Volume	30
Issue number	6
Early online date	26 Apr 2014
DOIs	https://doi.org/10.1016/j.pt.2014.04.003
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pt.2014.04.003Licence: CC BY

Publisher final version
2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/). http://dx.doi.org/10.1016/j.pt.2014.04.003
Final published version, 571 KBLicence: CC BY

Cite this

@article{bd4ca99f451a4013ae9adccae440b8de,

title = "Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects",

abstract = "There is an urgent need for new, safer, and effective treatments for the diseases caused by the protozoan parasites Trypanosoma brucei, Trypanosoma cruzi, and Leishmania spp. In the search for more effective drugs to treat these 'neglected diseases' researchers have chosen to reassess the therapeutic value of nitroaromatic compounds. Previously avoided in drug discovery programs owing to potential toxicity issues, a nitro drug is now being used successfully as part of a combination therapy for human African trypanosomiasis. We describe here the rehabilitation of nitro drugs for the treatment of trypanosomatid diseases and discuss the future prospects for this compound class.",

author = "Stephen Patterson and Susan Wyllie",

year = "2014",

doi = "10.1016/j.pt.2014.04.003",

language = "English",

volume = "30",

pages = "289--298",

journal = "Trends in Parasitology",

issn = "1471-4922",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Nitro drugs for the treatment of trypanosomatid diseases

T2 - past, present, and future prospects

AU - Patterson, Stephen

AU - Wyllie, Susan

PY - 2014

Y1 - 2014

N2 - There is an urgent need for new, safer, and effective treatments for the diseases caused by the protozoan parasites Trypanosoma brucei, Trypanosoma cruzi, and Leishmania spp. In the search for more effective drugs to treat these 'neglected diseases' researchers have chosen to reassess the therapeutic value of nitroaromatic compounds. Previously avoided in drug discovery programs owing to potential toxicity issues, a nitro drug is now being used successfully as part of a combination therapy for human African trypanosomiasis. We describe here the rehabilitation of nitro drugs for the treatment of trypanosomatid diseases and discuss the future prospects for this compound class.

AB - There is an urgent need for new, safer, and effective treatments for the diseases caused by the protozoan parasites Trypanosoma brucei, Trypanosoma cruzi, and Leishmania spp. In the search for more effective drugs to treat these 'neglected diseases' researchers have chosen to reassess the therapeutic value of nitroaromatic compounds. Previously avoided in drug discovery programs owing to potential toxicity issues, a nitro drug is now being used successfully as part of a combination therapy for human African trypanosomiasis. We describe here the rehabilitation of nitro drugs for the treatment of trypanosomatid diseases and discuss the future prospects for this compound class.

UR - http://www.scopus.com/inward/record.url?scp=84899035082&partnerID=8YFLogxK

U2 - 10.1016/j.pt.2014.04.003

DO - 10.1016/j.pt.2014.04.003

M3 - Article

C2 - 24776300

SN - 1471-4922

VL - 30

SP - 289

EP - 298

JO - Trends in Parasitology

JF - Trends in Parasitology

IS - 6

ER -

Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

A Translational Engine for Biomedical Discoveries (Strategic Grant)

Discovery and Development of Drug Candidates for Neglected Diseases (joint with industrial partner)

Aref#d: 18185. Characterization and validation of drug targets in the Kinetoplastida (Principal Research Fellowship/Programme Grant)

Cite this

Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

A Translational Engine for Biomedical Discoveries (Strategic Grant)

Discovery and Development of Drug Candidates for Neglected Diseases (joint with industrial partner)

Aref#d: 18185. Characterization and validation of drug targets in the Kinetoplastida (Principal Research Fellowship/Programme Grant)

Cite this